2020
DOI: 10.1016/s1470-2045(20)30147-9
|View full text |Cite
|
Sign up to set email alerts
|

Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
86
0
2

Year Published

2020
2020
2022
2022

Publication Types

Select...
3
3
2

Relationship

0
8

Authors

Journals

citations
Cited by 100 publications
(99 citation statements)
references
References 29 publications
4
86
0
2
Order By: Relevance
“… 16 , 17 In one study using UGN-101 in the upper tracts, only one patient developed pancytopenia. 9 These pharmacologic results were confirmed in an animal study using retrograde instillation of UGN-101 at once-weekly intervals for 6 consecutive weeks. 18 …”
Section: Development Safety and Feasibility Of Ugn-101: Preclinical mentioning
confidence: 68%
See 2 more Smart Citations
“… 16 , 17 In one study using UGN-101 in the upper tracts, only one patient developed pancytopenia. 9 These pharmacologic results were confirmed in an animal study using retrograde instillation of UGN-101 at once-weekly intervals for 6 consecutive weeks. 18 …”
Section: Development Safety and Feasibility Of Ugn-101: Preclinical mentioning
confidence: 68%
“…Final results with longer follow up were just published and consistent with these same outcomes. 9 The OLYMPUS study is the first well-designed, prospective trial to demonstrate a complete and durable chemo-ablative response to intracavitary therapy for low-grade UTUC. Since the unique hydrogel is technically considered a delivery device, the compound is considered a drugdevice combination, and indeed, was recently approved by the FDA as the first treatment for low-grade UTUC.…”
Section: Use Of MMC and Ugn-101 For Treatment Of Utuc: Retrospective mentioning
confidence: 99%
See 1 more Smart Citation
“…Improving outcomes for UTUC may include consideration of novel ablative technologies which have been introduced in the lower urinary tract. Overall, patient selection for endoscopic treatment remains critical and consideration must also be given to multimodal therapy with topical chemotherapeutic strategies [ 10 ].…”
Section: Discussionmentioning
confidence: 99%
“…In the search for new effective therapies to combine with surgery, low‐grade urothelial carcinoma represents a challenge for clinical research, and few advances have been made in medical therapy in the last decades. Very recently, alternative techniques of chemotherapy delivery, represented by UGN‐101, a mitomycin‐containing reverse thermal gel, have been tested in a phase 3 study, resulting in pathological complete responses in almost 60% of patients with low‐grade upper tract urothelial carcinoma [4]. Based on these results, UGN‐101 has been approved by the US Food and Drug Administration.…”
mentioning
confidence: 99%